

ASX Release

David Phillips to Lead Business Development

PERTH, AUSTRALIA – 25 JULY 2018: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, today announced that David Phillips will lead the business development for SUDA as the company moves into a new growth phase.

As previously announced, David was appointed as an advisor to the Board in November 2017 and then joined the Board in April 2018. David has over 30 years of experience in the global healthcare industry, including 14 years in sales and marketing with Glaxo Wellcome, Cephalon Inc, Oxford Molecular Group Plc, and eight years with SR One (GlaxoSmithKline's corporate venture fund).

David re-joined GlaxoSmithKline's (GSK) SR One corporate venture arm in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and in parallel investing in early-stage life science companies.

David has a strong track record in business development (BD) with approximately 50 BD deals completed in the Biotech/Pharmaceutical industry and 10 M&A transactions completed.

David will be seeking to appoint a representative in the US to promote the products in that market. David will take over all discussions with potential partners including companies specifically interested in our current pipeline and new potential products including cannabinoids.

The Board would like to acknowledge the work performed by Nick Woolf who has held the role as Chief Business Officer and who has chosen to step down after driving the BD activities for the last 5 years. Nick has successfully introduced the SUDA name throughout the pharmaceutical industry and the Company is now a recognised player in drug delivery technology.



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER/MANAGING DIRECTOR

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 5555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. ZolpiMist is partnered with Eddingpharm in China and Teva Pharmaceuticals in Latin America. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of migraine headache, chemotherapy-induced nausea and vomiting, erectile dysfunction, PAH, epileptic seizures and pre-procedural anxiety. For more information, visit www.sudapharma.com